Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH

ACR Convergence 2021

ACR Convergence 2021

ORAL Surveillance: Tofacitinib fails to show noninferiority vs TNF inhibitors for MACE, malignancy risk

The JAK inhibitor tofacitinib is associated with numerically higher rates of MACE and malignancy than TNF inhibitors in people with RA at high CV risk, show the ORAL Surveillance results.

ACR Convergence 2021

Olokizumab benefits extend to patients with RA refractory to methotrexate or TNF inhibitors

Olokizumab shows clinical and physical benefits for patients with rheumatoid arthritis (RA) with inadequate responses to methotrexate and tumor necrosis inhibitor (TNF) inhibitor therapy in the latest CREDO findings. Read now

ACR Convergence 2021

Add-on treatment for lupus nephritis: Should belimumab or voclosporin be used first?

In “The Great Debate”, experts discussed which new add-on treatment option should be used first for patients with active lupus nephritis despite conventional therapy. Read now

Expert video interviews from ACR Convergence 2021

12-11-2021 | ACR 2021 | Conference coverage | Video

Olokizumab: What makes it an effective and novel treatment for RA?

Roy Fleischmann discusses the implications of the CREDO2 and 3 trial findings looking at olokizumab efficacy versus adalimumab as an add-on to methotrexate and in TNF inhibitor non-responders.

07-11-2021 | ACR 2021 | Conference coverage | Video

Risankizumab for PsA: How will the KEEPsAKE 1 and 2 findings impact clinical practice?

Laura Coates comments on the results of the KEEPsAKE 1 and 2 studies, and explores where risankizumab may fit in the treatment landscape for psoriatic arthritis.

06-11-2021 | ACR 2021 | Conference coverage | Video

The ARIAA trial of abatacept for subclinical arthritis

Jürgen Rech outlines the findings from the ARIAA trial, which demonstrated benefits of abatacept in people at risk for rheumatoid arthritis, and discusses the potential role of treating subclinical inflammation to delay or prevent the onset of clinical disease.

Tofacitinib safety

ORAL Surveillance: Tofacitinib fails to show noninferiority vs TNF inhibitors for MACE, malignancy risk

10-11-2021 ACR 2021 Conference coverage

Real-world study suggests no elevated CV risk with tofacitinib in overall RA population

11-11-2021 ACR 2021 Conference coverage

Treatments for systemic lupus erythematosus, lupus nephritis

Add-on treatment for lupus nephritis: Should belimumab or voclosporin be used first?

08-11-2021 ACR 2021 Conference coverage

BLISS-BELIEVE: Adding rituximab to belimumab does not improve SLE disease control

09-11-2021 ACR 2021 Conference coverage

Phase 2 trial supports further investigation of iberdomide for SLE

09-11-2021 ACR 2021 Conference coverage

​​​​​​​AURORA 2 shows enduring proteinuria benefits with voclosporin in lupus nephritis

10-11-2021 ACR 2021 Conference coverage

Lupus nephritis patients may experience declining kidney function despite proteinuria resolution

08-11-2021 ACR 2021 Conference coverage

Treat-to-target strategies in gout

Data support serum urate-based treat-to-target approach in gout

06-11-2021 ACR 2021 Conference coverage

​​​​​​​Reassurance on CV risk with treat-to-target strategies in gout

09-11-2021 ACR 2021 Conference coverage

Early rheumatoid arthritis studies

Abatacept shows potential for subclinical arthritis

06-11-2021 ACR 2021 Conference coverage

Targeting unmet needs could improve QoL in early RA

06-11-2021 ACR 2021 Conference coverage

Piclidenoson misses primary endpoint for early RA

09-11-2021 ACR 2021 Conference coverage

More news from ACR Convergence 2021

Telemedicine feasible for delivery of SLE follow-up care

12-11-2021 ACR 2021 Conference coverage

Adherence to a treat-to-target approach in RA not hindered by virtual vs face-to-face visits

11-11-2021 ACR 2021 Conference coverage

High BMI may adversely affect PsA treatment response

10-11-2021 ACR 2021 Conference coverage

Increased risk for breakthrough COVID-19 infection in vaccinated patients with AIRDs

10-11-2021 ACR 2021 Conference coverage

IL-17A inhibition demonstrates potential for giant cell arteritis

10-11-2021 ACR 2021 Conference coverage

No benefit to methotrexate use with ustekinumab in PsA

09-11-2021 ACR 2021 Conference coverage

Pirfenidone shows promise for patients with RA-ILD

09-11-2021 ACR 2021 Conference coverage

Olokizumab benefits extend to patients with RA refractory to methotrexate or TNF inhibitors

09-11-2021 ACR 2021 Conference coverage

Statins show CVD benefits in RA with only a modest risk for new-onset diabetes

09-11-2021 ACR 2021 Conference coverage

COVID-19 vaccine response factors identified in rituximab-treated patients

09-11-2021 ACR 2021 Conference coverage

Improved renal outcomes in children with lupus overshadowed by racial disparities

08-11-2021 ACR 2021 Conference coverage

Positive phase 2b results for ianalumab in primary Sjögren’s syndrome

08-11-2021 ACR 2021 Conference coverage

Research allays concerns over TNF inhibitor use in HIV-positive patients

08-11-2021 ACR 2021 Conference coverage

Tocilizumab candidate for glucocorticoid-sparing agent in polymyalgia rheumatica

07-11-2021 ACR 2021 Conference coverage

Brepocitinib shows promise in psoriatic arthritis

07-11-2021 ACR 2021 Conference coverage

Belimumab, arimoclomol disappoint in myositis trials

07-11-2021 ACR 2021 Conference coverage

US study identifies racial disparities in lupus nephritis mortality

07-11-2021 ACR 2021 Conference coverage

High rates of severe COVID-19 in patients with vasculitis, polymyalgia rheumatica

07-11-2021 ACR 2021 Conference coverage

KEEPsAKE trials show benefits of risankizumab in patients with PsA

06-11-2021 ACR 2021 Conference coverage

Observational data show patterns of neurologic, ocular manifestations in ANCA-associated vasculitis

06-11-2021 ACR 2021 Conference coverage


This information is brought to you by Medicine Matters in partnership with medwireNews and is not sponsored by, nor a part of, the American College of Rheumatology.


Image Credits